Rubric Capital Management (New York)’s Werewolf Therapeutics HOWL Stock Holding History

Rubric Capital Management (New York)’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,333,893	Closed	-$1.3M	–	68
2025 Q1	$1.3M	Hold	1,333,893	–	–	0.02%	64
2024 Q4	$1.97M	Hold	1,333,893	–	–	0.03%	67
2024 Q3	$2.83M	Hold	1,333,893	–	–	0.05%	60
2024 Q2	$3.25M	Sell	1,333,893 -287,141	-18%	-$1.38M	0.09%	64
2024 Q1	$10.5M	Sell	1,621,034 -314,323	-16%	-$1.83M	0.31%	56
2023 Q4	$7.47M	Hold	1,935,357	–	–	0.16%	49
2023 Q3	$4.14M	Hold	1,935,357	–	–	0.16%	56
2023 Q2	$5.9M	Hold	1,935,357	–	–	0.25%	53
2023 Q1	$5.03M	Buy	1,935,357 +99,970	+5%	+$298K	0.13%	62
2022 Q4	$3.76M	Buy	1,835,387 +868,508	+90%	+$2.27M	0.16%	79
2022 Q3	$4.36M	Buy	966,879 +761,883	+372%	+$4.14M	0.22%	64
2022 Q2	$838K	Buy	+204,996	New	+$935K	0.04%	87

Other funds holding HOWL

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Rubric Capital Management (New York)'s HOWL Position: Q2 2025 in Review

Rubric Capital Management (New York) sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 1,333,893 shares — an estimated $1.3M sold.

Rubric Capital Management (New York) first reported a position in HOWL in Q2 2022 and held it in 12 quarters. The position peaked at $10.5M in Q1 2024. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

Rubric Capital Management (New York) reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
Rubric Capital Management (New York) sold 1,333,893 Werewolf Therapeutics shares in Q2 2025, an estimated $1.3M.
Rubric Capital Management (New York) first reported a position in Werewolf Therapeutics in Q2 2022 and held it in 12 quarters.
Rubric Capital Management (New York)'s Werewolf Therapeutics position peaked at $10.5M in Q1 2024.
65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2025, filed 14 Aug 2025.